[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Daniel Raskas Biography and Net Worth

SVP of Danaher

As Senior Vice President, Corporate Development, Daniel Raskas leads mergers and acquisitions in partnership with Bill King and oversees investment activity, including identification, valuation, due diligence, contract strategy and negotiations.

Daniel joined Danaher in 2004, originally serving as Vice President of Corporate Development, and was promoted to his current role in 2010. Throughout his tenure, he has led business development across the company and overseen a number of major acquisitions, including Beckman Coulter, Pall and Cytiva.

Before joining Danaher, Daniel was a partner at Thayer Capital Partners, a private equity firm focused on buyout and growth equity investments in the middle market. He also served as an associate at Arnold & Porter LLP for several years, where he specialized in transactional work including M&A and public offerings.

Daniel received a B.A. in Government from Harvard College, an M.B.A. from Columbia University School of International and Public Affairs, and a J.D. from Harvard Law School.

What is Daniel Raskas' net worth?: The estimated net worth of Daniel Raskas is at least $8.88 million as of February 26th, 2024. Mr. Raskas owns 38,102 shares of Danaher stock worth more than $8,881,576 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Raskas may own. Learn More about Daniel Raskas' net worth.
How do I contact Daniel Raskas?: The corporate mailing address for Mr. Raskas and other Danaher executives is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. Danaher can also be reached via phone at (202) 828-0850 and via email at [email protected]. Learn More on Daniel Raskas' contact information.
Has Daniel Raskas been buying or selling shares of Danaher?: Daniel Raskas has not been actively trading shares of Danaher over the course of the past ninety days. Most recently, Daniel Raskas sold 23,757 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a transaction totalling $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company's stock, valued at $9,601,704. Learn More on Daniel Raskas' trading history.
Who are Danaher's active insiders?: Danaher's insider roster includes Rainer Blair (President, CEO & Director), Daniel Comas (EVP), Georgeann Couchara (SVP), William Daniel (EVP), Brian Ellis (SVP), Linda Filler (Director), Jose-Carlos Gutierrez-Ramos (SVP), Linda Hefner (Director), Jennifer Honeycutt (EVP), Thomas Joyce, Jr. (CEO), William King (SVP), Angela Lalor (SVP), Angela Lalor (SVP), Teri List (Director), Walter Lohr (Director), Robert Lutz (CAO), Matthew McGrew (CFO), Mitchell Rales (Chairman), Daniel Raskas (SVP), John Schwieters (Director), Alan Spoon (Director), Raymond Stevens (Director), Joakim Weidemanis (EVP), and Elias Zerhouni (Director). Learn More on Danaher's active insiders.
Are insiders buying or selling shares of Danaher?: In the last twelve months, insiders at the conglomerate sold shares 16 times. They sold a total of 221,399 shares worth more than $56,844,951.46. The most recent insider tranaction occured on August, 26th when SVP Georgeann Couchara sold 952 shares worth more than $255,488.24. Insiders at Danaher own 10.9% of the company. Learn More about insider trades at Danaher.
Information on this page was last updated on 8/26/2024.

Daniel Raskas Insider Trading History at Danaher

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/26/2024	Sell	23,757	$252.00	$5,986,764.00	38,102
7/28/2023	Sell	11,213	$260.65	$2,922,668.45	38,288
5/31/2023	Sell	19,847	$228.50	$4,535,039.50	38,673
11/26/2021	Sell	12,300	$325.33	$4,001,559.00
10/23/2020	Sell	28,389	$234.50	$6,657,220.50	38,850
5/8/2020	Sell	37,082	$164.09	$6,084,785.38	19,723
11/16/2017	Sell	37,870	$93.33	$3,534,407.10
2/26/2016	Sell	4,656	$89.00	$414,384.00	17,786
2/26/2015	Sell	4,179	$87.79	$366,874.41
2/20/2015	Sell	56,000	$87.03	$4,873,680.00
5/1/2014	Sell	11,158	$73.48	$819,889.84	18,368
10/18/2013	Sell	20,000	$71.99	$1,439,800.00
7/24/2013	Sell	20,000	$67.54	$1,350,800.00

Daniel Raskas Buying and Selling Activity at Danaher

Danaher Company Overview

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Today's Range

Now: $233.10

$228.89

$233.73

50 Day Range

MA: $259.67

$229.50

$278.02

2 Week Range

Now: $233.10

$213.61

$281.70

Volume

2,642,129 shs

Average Volume

3,170,196 shs

Market Capitalization

$168.36 billion

P/E Ratio

44.48

Dividend Yield

0.47%

Beta

0.85